Log in to save to my catalogue

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2299141735

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy after having had a response to platinum-based chemotherapy. Progression-free survival was significantly longer in the niraparib group than in the placebo group, with some increase in the freque...

Alternative Titles

Full title

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2299141735

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2299141735

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1910962

How to access this item